Market Cap 164.8B
Revenue (FYR) $62.5B
EPS (TTM) $4.87
Shares Out. 2.7B
Book Value $20.85
Dividend Yield 3.60%
Div/Share $2.16
P/E 12.3x
Price/Sales (FYR) 2.6
P/Cash Flow (TTM) 10.0x
Johnson & Johnson
is a profitable Major Drugs company JNJ is engaged in the
research and development, manufacture and sale of a range of
products in the healthcare field. Johnson & Johnson has more
than 250 operating companies.
The Company operates in three
segments. The Consumer segment includes a range of products
used in the baby care, skin care, oral care, wound care and
women's healthcare fields, as well as nutritional and
over-the-counter pharmaceutical products.
The Pharmaceutical
segment includes products in the therapeutic areas, such as
anti-infective, antipsychotic, cardiovascular,
contraceptive, dermatology, gastrointestinal, hematology,
immunology, neurology, oncology, pain management, urology
and virology.
The Medical Devices and Diagnostics segment
includes a range of products distributed to wholesalers,
hospitals and retailers. In July 2009, Johnson & Johnson
completed the acquisition of Cougar Biotechnology, Inc. with
approximately 95.9% interest in Cougar Biotechnology's
outstanding common stock.
|